Daratumumab (Dara) is the first-in-class human-specific anti-CD38 mAb approved for the treatment of multiple myeloma (MM). Although recent data have demonstrated very promising results in clinical practice and trials, some patients do not achieve a partial response, and ultimately all patients undergo progression. Dara exerts anti-MM activity via antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and immunomodulatory effects. Deregulation of these pleiotropic mechanisms may cause development of Dara resistance. Knowledge of this resistance may improve the therapeutic management of MM patients
Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
Saltarella, Ilaria;Desantis, Vanessa;Melaccio, Assunta;Solimando, Antonio Giovanni;Lamanuzzi, Aurelia;Ria, Roberto;Storlazzi, Clelia Tiziana;Mariggiò, Maria Addolorata;Vacca, Angelo
;
2020-01-01
Abstract
Daratumumab (Dara) is the first-in-class human-specific anti-CD38 mAb approved for the treatment of multiple myeloma (MM). Although recent data have demonstrated very promising results in clinical practice and trials, some patients do not achieve a partial response, and ultimately all patients undergo progression. Dara exerts anti-MM activity via antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and immunomodulatory effects. Deregulation of these pleiotropic mechanisms may cause development of Dara resistance. Knowledge of this resistance may improve the therapeutic management of MM patients| File | Dimensione | Formato | |
|---|---|---|---|
|
101.pdf
accesso aperto
Descrizione: Articolo in rivista
Tipologia:
Documento in Versione Editoriale
Licenza:
Creative commons
Dimensione
707.53 kB
Formato
Adobe PDF
|
707.53 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
